MA33409B1 - Produits de recombinaisoon de casb7439 - Google Patents

Produits de recombinaisoon de casb7439

Info

Publication number
MA33409B1
MA33409B1 MA34476A MA34476A MA33409B1 MA 33409 B1 MA33409 B1 MA 33409B1 MA 34476 A MA34476 A MA 34476A MA 34476 A MA34476 A MA 34476A MA 33409 B1 MA33409 B1 MA 33409B1
Authority
MA
Morocco
Prior art keywords
casb7439
recombination products
methods
recombination
products
Prior art date
Application number
MA34476A
Other languages
Arabic (ar)
English (en)
Inventor
Normand Blais
Martine Harvey
Anthony Pilorget
Clément Rioux
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA33409B1 publication Critical patent/MA33409B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des composés et des procédés pour l'augmentation de la production par recombinaison de polypeptides CASB7439 et sur leurs procédés d'utilisation.
MA34476A 2009-05-27 2010-05-25 Produits de recombinaisoon de casb7439 MA33409B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18138009P 2009-05-27 2009-05-27
US22039609P 2009-06-25 2009-06-25
PCT/EP2010/057141 WO2010136443A1 (fr) 2009-05-27 2010-05-25 Produits de recombinaison de casb7439

Publications (1)

Publication Number Publication Date
MA33409B1 true MA33409B1 (fr) 2012-07-03

Family

ID=42556967

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34476A MA33409B1 (fr) 2009-05-27 2010-05-25 Produits de recombinaisoon de casb7439

Country Status (19)

Country Link
US (1) US8916514B2 (fr)
EP (1) EP2435469A1 (fr)
JP (1) JP2012528106A (fr)
KR (1) KR20120014054A (fr)
CN (1) CN102459324B (fr)
AU (1) AU2010252012A1 (fr)
BR (1) BRPI1012078A2 (fr)
CA (1) CA2763486A1 (fr)
CL (1) CL2011002994A1 (fr)
CO (1) CO6400229A2 (fr)
DO (1) DOP2011000348A (fr)
EA (1) EA020617B1 (fr)
IL (1) IL216351A0 (fr)
MA (1) MA33409B1 (fr)
MX (1) MX2011012623A (fr)
NZ (1) NZ596501A (fr)
PE (1) PE20120400A1 (fr)
SG (1) SG176220A1 (fr)
WO (1) WO2010136443A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143425D1 (de) 2000-02-23 2010-12-23 Smithkline Beecham Biolog Neue verbindungen
DK2266603T3 (da) * 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa Tumorvacciner
US20140171626A1 (en) * 2012-12-19 2014-06-19 Glaxosmithkline Llc Protein purification
WO2016146143A1 (fr) 2015-03-16 2016-09-22 Amal Therapeutics Sa Peptides pénétrant dans les cellules et complexes comprenant ceux-ci
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
LT3429618T (lt) 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
WO2018055060A1 (fr) * 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprenant un peptide de pénétration cellulaire, un multi-épitope et un agoniste des peptides tlr pour le traitement du cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300883A (es) 1992-02-18 1994-08-31 Smithkline Beecham Corp Polipeptidos de vacuna.
AU8116494A (en) 1993-11-12 1995-06-13 Kenichi Matsubara Gene signature
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
ES2301175T3 (es) 1996-02-09 2008-06-16 Smithkline Beecham Biologicals S.A. Vacunas contra el producto del gen 63 del virus de la varicela zoster.
TR200002284T2 (tr) 1998-02-05 2000-11-21 Smithkline Beecham Biologicals S.A. Mage ailesinden tümör ile ilgili tümör türevleri
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
ES2273482T3 (es) 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Composiciones de vacunas combinadas.
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
IL145047A0 (en) 1999-03-11 2002-06-30 Smithkline Beecham Biolog Casb618 polynucleotides and polypeptides and their use
WO2001002828A2 (fr) 1999-07-07 2001-01-11 Tularik Inc. Diagnostic du cancer par detection de polynucleotides ou de polypeptides ash2
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
DE60143425D1 (de) * 2000-02-23 2010-12-23 Smithkline Beecham Biolog Neue verbindungen
US7811574B2 (en) * 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US8039602B2 (en) 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
GB0104259D0 (en) * 2001-02-21 2001-04-11 Smithkline Beecham Biolog Novel compounds
GB0111974D0 (en) * 2001-05-16 2001-07-04 Glaxosmithkline Biolog Sa Novel Compounds
JP2006512901A (ja) * 2002-08-29 2006-04-20 ジェネンテック・インコーポレーテッド Ａｃｈａｅｔｅ−Ｓｃｕｔｅ様−２ポリペプチドとそのコード化核酸並びに腫瘍の診断と治療のための方法
US20080108070A1 (en) * 2006-09-08 2008-05-08 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of colon cancer
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy

Also Published As

Publication number Publication date
SG176220A1 (en) 2011-12-29
NZ596501A (en) 2013-11-29
WO2010136443A1 (fr) 2010-12-02
CN102459324A (zh) 2012-05-16
DOP2011000348A (es) 2012-01-15
CO6400229A2 (es) 2012-03-15
US8916514B2 (en) 2014-12-23
PE20120400A1 (es) 2012-05-04
KR20120014054A (ko) 2012-02-15
IL216351A0 (en) 2012-01-31
EA201190274A1 (ru) 2012-06-29
BRPI1012078A2 (pt) 2019-09-24
CL2011002994A1 (es) 2012-07-20
EP2435469A1 (fr) 2012-04-04
EA020617B1 (ru) 2014-12-30
AU2010252012A1 (en) 2011-12-22
CN102459324B (zh) 2014-07-09
JP2012528106A (ja) 2012-11-12
MX2011012623A (es) 2011-12-14
US20120070491A1 (en) 2012-03-22
CA2763486A1 (fr) 2010-12-02

Similar Documents

Publication Publication Date Title
MA33409B1 (fr) Produits de recombinaisoon de casb7439
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
MA33423B1 (fr) Différentiation de cellules souches mésenchymateuses
MX2011003473A (es) Composiciones para el cuidado bucal.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
TN2011000673A1 (en) Bace inhibitors
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
FR2923364B1 (fr) Recipient pour produits cosmetiques
FR2924579B1 (fr) Recipient pour produits cosmetiques
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
DE602007012072D1 (de) Orantagonisten
MX2011007101A (es) Composiciones de hidrolizados proteicos que tienen capacidad mejorada para liberar colecistocinina (cck).
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
EP2569330A4 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2009005829A (es) Polialquileniminas hidrofobicamente modificadas para usarse como inhibidores de transferencia de colorante.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
MY161868A (en) Anti-bv8 antibodies and uses thereof
BR112012018402A2 (pt) "produto refratário com elevado teor de zircônio".
MX2009011648A (es) Componente estructural a base de un material ceramico.
EP2649025A4 (fr) Produits d'amélioration de force adhésive pour des compositions cimentaires
MX2009013921A (es) Material refractario sin forma, un proceso para producir un material refractario sin forma, humedo como la tierra, y al uso del material refractario sin forma.
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.